Adaptimmune Therapeutics reported a net loss of $74.2 million for the fourth quarter of 2024, translating to $(0.05) per diluted ordinary share. This financial result was disclosed in the company's Form 10-K Annual Report, filed after the market closed on March 24, 2025.
The reported net loss was primarily influenced by non-recurring restructuring costs, which amounted to $6.0 million during the quarter. This financial outcome follows the company's earlier announcement of a strategic restructuring, including a 29% reduction in headcount, aimed at reducing operating expenses.
The company's Annual Report also disclosed substantial doubt about its ability to continue as a going concern, indicating that its existing cash and marketable securities are not sufficient to fund operations for at least the next 12 months. This financial performance and outlook underscore the ongoing challenges Adaptimmune faces in achieving profitability despite its commercial and pipeline progress.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.